Doxorubicin-Anchored Curcumin Nanoparticles for Multimode Cancer Treatment against Human Liver Carcinoma Cells

Abstract

1028 wileyonlinelibrary.com www.particle-journal.com www.MaterialsViews.com Curcumin ( Curcuma longa L), a yellow-colored Indian spice, receives immense attention for the prevention and treatment of various cancers. Despite the superlative therapeutic effi cacy, its poor solubility and instability in the aqueous medium hinder the effectiveness of cancer treatment. The novel preparation of curcumin nanoparticles by mechanical grinding of curcumin crystals without any toxic organic solvents is described here for the fi rst time. The surface of curcumin nanoparticles is modifi ed with the negatively charged polyelectrolyte poly(sodium 4-strynesulfonate) through hydrogen bonding, which is the key to increasing the solubility and stability in the aqueous medium. The negative surface charge is exploited to conjugate doxorubicin drug molecule on the surface of curcumin nanoparticles as evidenced by fl uorescence quenching experiments. Doxorubicin-conjugated curcumin nanoparticles have a higher solubility with an enhanced cytotoxic effect toward the human hepatocellular carcinoma cell line by a reactiveoxygen-species-mediated p53-dependent apoptotic pathway. The combination of chemotherapy and photodynamic therapy signifi cantly enhances antitumor activity of doxorubicin-conjugated curcumin nanoparticles, and is expected to be a promising anticancer agent with special reference to human liver carcinoma cells.

Preclinical Assessment of Enhanced Chemodynamic Therapy by an FeMnOx-Based Nanocarrier: Tumor-Microenvironment-Mediated Fenton Reaction and ROS-Induced Chemotherapeutic for Boosted Antitumor Activity

“…Hemocompatibility is a crucial consideration for nanoparticles to guarantee their compatibility in biomedical uses, particularly when these materials come into contact with blood. , The impact of FeMnO x NPs and FeMnO x @CPT on the blood was assessed using a hemolysis assay with mouse blood cells. As depicted in Figures a–c, neither FeMnO x NPs nor FeMnO x @CPT exhibited any negative effects on the number of red blood cells (RBCs) in comparison to the positive controls at the assessed dosage.…”

“…Hemolysis experiments were performed in vitro according to earlier reports. , In short, fresh whole blood specimens fixed with ethylenediamine tetraacetic acid (EDTA) were taken from a healthy mouse. To extract serum from whole blood, it was centrifuged at 3000 rpm for 10 min to pick up the red blood cells (RBCs).…”

Application of the Box–Behnken design for the production of soluble curcumin: Skimmed milk powder inclusion complex for improving the treatment of colorectal cancer

“…Briefly, the IC 50 concentration of compounds was used to treat the cells for 24 hr, which were then washed with cold PBS. Cells were then resuspended in PBS at a concentration of 5 × 10 5 cells/ml and then mixed with 25 µl of AO/EB solution (3.8 µM of AO and 2.5 µM of EB in PBS) on a clean slide (Rajiu et al., 2015). These samples were quickly analyzed by fluorescence microscopy (Carl Zeiss, Axioscope 2plus) with a UV filter (450−490 nm).…”

Effective delivery of hydrophobic drugs to breast and liver cancer cells using a hybrid inorganic nanocarrier: A detailed investigation using cytotoxicity assays, fluorescence imaging and flow cytometry

“…a. and b., low hemolytic percentages well below 1.5%, suggest the hemocompatibility of the nanoparticles. These values are very low compared with the reported work on these drugs and similar drug loaded nanoparticles [19], [61]. All the drug loaded nanoparticles are critically safe to be used for cancer treatment, as recommended by ISO/TR 7406 [61].…”